Tag: amcenestrant
Sanofi: stops the clinical development of amcenestrant
By Jean-Baptiste Andre Published on 08/17/2022 at 07:54 Photo credit © Sanofi (Boursier.com)…
Sanofi stops the development of amcenestrant, the title drops
Published on 08/17/2022 at 11:22 Photo credit © Reuters PARIS (Reuters) –…
Sanofi stops the amcenestrant development program (breast cancer) – 08/17/2022 at 08:15
(AOF) – Sanofi has terminated the global clinical development program for amcenestrant, an oral treatment for certain breast cancers. “An independent data monitoring committee found that, compared to the control…
Sanofi: ends the amcenestrant program – 08/17/2022 at 14:14
(CercleFinance.com) – Sanofi announces that it is ending the worldwide clinical development program for amcenestrant, an experimental selective estrogen receptor deregulator (SERD) taken by mouth. This decision is based on…
Sanofi halts development of amcenestrant, adjuvant treatment in breast cancer
Sanofi stops the development of lamcenestrant, adjuvant treatment in breast cancer | Photo credits: Sanofi Pasteur/Randy Monceaux PARIS, Aug 17 (Reuters) – Sanofi announced in a press release on Wednesday…
Sanofi ends global clinical development program for amcenestrant
Sanofi terminates global clinical development program for lamcenestrant | Photo credits: Sanofi Pasteur – Alexis Chezière PARIS (Agefi-Dow Jones)–The pharmaceutical group Sanofi announced on Wednesday that it is ending the…
Sanofi stops the development of amcenestrant, the title drops
(updated with analyst commentary § 5-6, share price §1) PARIS, Aug 17 (Reuters) – Sanofi shares opened lower on the Paris Stock Exchange on Wednesday, falling 1.14% at the start…
Sanofi: amcenestrant trial failed to meet primary endpoint
PARIS (Agefi-Dow Jones)–The pharmaceutical group Sanofi announced on Monday that the AMEERA-3 phase 2 trial evaluating amcenestrant in the treatment of advanced or metastatic breast cancer had not met its…
Sanofi: Failure of a phase II trial on amcenestrant
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Sanofi provides an update on the phase II study evaluating amcenestrant in the treatment of advanced or metastatic ER+/HER2- breast cancer – 03/14/2022 at 07:00
Sanofi takes stock of the phase II study evaluating the amcenestrant in the treatment of breast cancer ER+/HER2- at an advanced or metastatic stage The AMEERA-3 trial failed to meet…
Sanofi: failure of a phase II trial on amcenestrant
(CercleFinance.com) – Sanofi announces that the AMEERA-3 phase II clinical trial evaluating amcenestrant did not meet its primary endpoint, namely improvement in progression-free survival, according to a centralized evaluation independent.…
Sanofi says study evaluating amcenestrant failed to meet primary endpoint
March 14 (Reuters) – Sanofi SA SASY.PA: * AMEERA-3 TRIAL DID NOT MEET ITS PRIMARY ENDPOINT – NO IMPROVEMENT IN SURVIVAL WITHOUT PROGRESSION * ONGOING TRIALS, INCLUDING AMEERA-5 AND AMEERA-6,…